相关实验视频

Updated: Jul 18, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

一个小分子BCL6抑制剂作为急性骨髓性白血病的化学敏感剂

Lin Zhang¹, Min Wu¹, Weikai Guo¹

¹Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dong Chuan Rd, Shanghai 200241, China.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|August 27, 2023

概括

一种新的化合物WK499针对BCL6,这是急性髓性白血病 (AML) 的一个因素. 这种小分子抑制剂在减少AML细胞增殖和增强化疗效方面表现有前途.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

急性髓性白血病 (AML) 的预后不好,化学疗法耐药性是一个主要的挑战.
BCL6是AML的关键瘤原因子,调节关键的细胞过程.

研究的目的:

确定和评估一种针对BCL6的小分子抑制剂,用于AML治疗.
在AML模型中评估单独和与化疗结合使用WK499的疗效.

主要方法:

识别WK499,一种与BCL6 BTB域结合的化合物.
在体外研究评估WK499对AML细胞增殖,细胞循环和细胞亡的影响.
在体内评估WK499与化疗剂 (AraC) 结合的研究.

主要成果:

WK499治疗破坏了BCL6的相互作用,导致AML细胞中的抗增殖效应和亡.
WK499与 AraC 和 Doxorubicin 等化疗药物表现出协同效应.
联合WK499和AraC在体内显著抑制了AML的生长.

结论:

WK499是一种强大的BCL6小分子抑制剂,具有直接的抗白血病活性.
WK499增强了AML对常规化疗的敏感性,提供了一个潜在的治疗策略.

关键词:

在AML,AML就是AML.在 BCL6 中.化学敏感剂化学敏感剂组合疗法是一种联合疗法.

更多相关视频

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...